Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT)
Tezepelumab provides early and sustained improvements in sense of smell among patients with uncontrolled CRSwNP.
Authors
- Claudia Chen
- Tanya M. Laidlaw (ORCID: https://orcid.org/0000-0001-6709-9795)
- ANJU T PETERS
- Andrew Lindsley (ORCID: https://orcid.org/0000-0003-2670-704X)
- Stella E. Lee (ORCID: https://orcid.org/0000-0001-6563-6606)
- Christopher S. Ambrose (ORCID: https://orcid.org/0000-0003-4175-7336)
- Andrew Foster (ORCID: https://orcid.org/0000-0002-0406-7558)
- Joaquim Mullol
- Dr O. Pfaar
- Joseph K. Han
- M. Desrosiers
- Claire Hopkins
- Sandhia S. Ponnarambil
- Andrew P. Lane
Institutions
- Northwestern University (US)
- Brigham and Women's Hospital (US)
- Amgen (United States) (US)
- St Thomas' Hospital (GB)
- Johns Hopkins University (US)
- Eastern Virginia Medical School (US)
- Philipps University of Marburg (DE)
- Johns Hopkins Medicine (US)
- Hospital Clínic de Barcelona (ES)
- St. Thomas Hospital (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- AstraZeneca (Spain) (ES)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- International Forum of Allergy & Rhinology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1002/alr.70090
- Citations
- 1
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 53.14
Funders
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Johns Hopkins University
- Regeneron Pharmaceuticals
- Insmed
- Mitsubishi Tanabe Pharma Corporation
- Menarini Group
- Genentech
- Sanofi Genzyme
- UCB Pharma